Related references
Note: Only part of the references are listed.A Pooled Analysis of Infections, Malignancy, and Mortality in Infliximab- and Immunomodulator-Treated Adult Patients With Inflammatory Bowel Disease
Gary R. Lichtenstein et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2012)
Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry
Gary R. Lichtenstein et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2012)
Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2012)
Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease
Mamoru Watanabe et al.
JOURNAL OF CROHNS & COLITIS (2012)
Efficacy of Biological Therapies in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis
Alexander C. Ford et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Certolizumab Pegol for Active Crohn's Disease: A Placebo-Controlled, Randomized Trial
William J. Sandborn et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2011)
A Systematic Review of Factors That Contribute to Hepatosplenic T-Cell Lymphoma in Patients With Inflammatory Bowel Disease
David S. Kotlyar et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2011)
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial
Walter Reinisch et al.
GUT (2011)
Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials
Jonathan A. C. Sterne et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine
T. T. MACDONALD et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2010)
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease.
Jean Frederic Colombel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Meta-analysis: the efficacy and safety of certolizumab pegol in Crohn's disease
L. -M. Shao et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
Infliximab Prevents Crohn's Disease Recurrence After Ileal Resection
Miguel Regueiro et al.
GASTROENTEROLOGY (2009)
Adalimumab Safety in Global Clinical Trials of Patients with Crohn's Disease
Jean-Frederic Colombel et al.
INFLAMMATORY BOWEL DISEASES (2009)
European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease
J. F. Rahier et al.
JOURNAL OF CROHNS & COLITIS (2009)
Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: Meta-analysis of placebo-controlled trials
Laurent Peyrin-Biroulet et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2008)
A Randomized Trial of Methotrexate in Combination With Infliximab for the Treatment of Crohn's Disease
Brian Feagan et al.
GASTROENTEROLOGY (2008)
Risk factors for opportunistic infections in patients with inflammatory bowel disease
Murat Toruner et al.
GASTROENTEROLOGY (2008)
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease:: an open randomised trial
Geert D'Haens et al.
LANCET (2008)
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial
W. J. Sandborn et al.
GUT (2007)
Certolizumab pegol for the treatment of Crohn's disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Maintenance therapy with certolizumab pegol for Crohn's disease
Stefan Schreiber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Adalimumab induction therapy for Crohn disease previously treated with infliximab - A randomized trial
William J. Sandborn et al.
ANNALS OF INTERNAL MEDICINE (2007)
Systematic review: infliximab therapy in ulcerative colitis
J. P. Gisbert et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2007)
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial
Jean-Frederic Colombel et al.
GASTROENTEROLOGY (2007)
Do anti-tumor necrosis factors induce response and remission in patients with acute refractory Crohn's disease? A systematic meta-analysis of controlled clinical trials
Roja Rahimi et al.
BIOMEDICINE & PHARMACOTHERAPY (2007)
Infliximab plus azathioprine for steroid-dependent Crohn's disease patients:: A randomized placebo-controlled trial
M Lémann et al.
GASTROENTEROLOGY (2006)
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial
SB Hanauer et al.
GASTROENTEROLOGY (2006)
Infliximab for induction and maintenance therapy for ulcerative colitis
P Rutgeerts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease
S Schreiber et al.
GASTROENTEROLOGY (2005)
Infliximab as rescue therapy in severe to moderately severe ulcerative colitis:: A randomized, placebo-controlled study
G Järnerot et al.
GASTROENTEROLOGY (2005)
Infliximab maintenance therapy for fistulizing Crohn's disease
BE Sands et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study
TA Winter et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2004)
Measuring inconsistency in meta-analyses
JPT Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2003)
Infliximab in moderately severe glucocorticoid resistant ulcerative colitis:: a randomised controlled trial
CSJ Probert et al.
GUT (2003)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
Tuberculosis associated with infliximab, a tumor necrosis factor (alpha)-neutralizing agent
J Keane et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: A pilot study
BE Sands et al.
INFLAMMATORY BOWEL DISEASES (2001)